Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Melanoma 1Glioma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

trametinib 3dabrafenib 3binimetinib 2Trastuzumab 2Paclitaxel 2Nivolumab 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Docetaxel 2ulixertinib 1trastuzumab biosimilar HLX02 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1larotrectinib 1ipatasertib 1glutathione pegylated liposomal doxorubicin 1erdafitinib 1entinostat 1diazepinomicin 1defactinib 1copanlisib 1cobimetinib 1clevudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × AH 111585 × Thoracic × Clear all
NCT00565721 2014-08-18

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

GE Healthcare

Phase 2 Completed
33 enrolled 23 charts
CNSDermatologicHead & NeckSarcomaThoracic

Glioma, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡